Skip to main content

Advertisement

Figure 3 | Arthritis Research & Therapy

Figure 3

From: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Figure 3

POC Component: Key Efficacy Endpoints (A) Effect of maraviroc on ACR20 response rate over time. (B) Least squares mean change from baseline in CRP over time. (C) Least squares mean change from baseline in DAS28-4 (CRP) over time; all figures used data from the full analysis set (FAS) with last observation carried forward(LOCF). ACR20, American College of Rheumatology 20% improvement criteria; BID, twice daily; CRP, C-reactive protein; DAS, disease activity score; DAS28-4 (CRP), disease activity score, 28-joint count, using C-reactive protein; FAS, full analysis set; LOCF, last observation carried forward; SEM, standard error of the mean.

Back to article page